Details

Purpose:To discuss  the scientific and public health underpinning of four of the all-time  largest device-based physical activity (PA) dose-response and non-communicable disease studies published in 2022, and to summarise equivalent ongoing dose-response work on sedentary behaviour (SB) and sleep. 

Rationale:More than 90% of the evidence used to inform the 2018 US and 2020 WHO guidelines came from observational cohort studies reliant on self-report data. The application of wearable devices to objectively measure movement in combination with novel processing techniques in population cohorts has the potential to revolutionise physical behaviour evidence to inform the next generation of physical activity, sedentary behaviour, and sleep guidelines. No unified physical behaviour classification framework for wrist accelerometry has been used or proposed to date. 

Objectives:We will highlight 4 published and summarise 2 in-progress prospective studies assessing the associations of physical behaviours with non-communicable diseases, through application of cutting-edge machine-learning techniques and the novel Unified Wrist Accelerometry Framework. 

Format and Summary:The chair will cover research gaps identified by the WHO Guidelines Development Group, including the need for prospective device-based evidence and the Unified Wrist Accelerometry Framework.(8 min).

Stewart Trost will present on the uptake and implementation of machine learning techniques with wearable-devices. (12 min).

          Borja del Pozo-Cruz will present on the 2 first-ever wrist accelerometry studies assessing the association of stepping behaviours with CVD/cancer/dementia risks (JAMA Internal Med 2022; JAMA Neurology 2022). (12 min).

          Matthew Ahmadi will present the first-ever wearable-device study examining dose-response of vigorous-activity duration and frequency. (12 min),  (European Heart Journal 2022).

      Emmanuel Stamatakis will present the first investigation of (non-exercise) vigorous intermittent lifestyle physical activity (VILPA) and mortality risk (Nature Medicine 2022) and summarise the two on-going device-based studies. (12 min). 

      The discussant will lead panel discussion and facilitate engagement from audience members (19 min)

      Interaction:The Discussant will facilitate a discussion with the presenter panel and audience on topics that extend from the individual presentations. These may include:

1)Guideline priorities on objective measures of physical activity as critical tools for public health policy, health surveillance, and community and clinical medicine. 

2)Pearls and pitfalls of updated health messaging from device-based vs questionnaire-based evidence. 

3)Previously unrealised health associations of non-exercise vigorous intermittent lifestyle physical activity and utility for intervention strategies. 

Speaker